Drug – bio-affecting and body treating compositions – Dermatitis – Eczema
Reexamination Certificate
2006-09-19
2006-09-19
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Dermatitis
Eczema
C514S937000, C514S715000
Reexamination Certificate
active
07109246
ABSTRACT:
A formulation, for example an oil-in-water emulsion, comprising an amphoteric surfactant, alkoxylated cetyl alcohol and a polar drug. The drug may be sodium cromoglycate or nedocromil sodium. The formulation may be useful in the treatment of skin disease such as atopic dermatitis.
REFERENCES:
patent: 4868192 (1989-09-01), Totten et al.
patent: 4883792 (1989-11-01), Timmins et al.
patent: 5000936 (1991-03-01), Chibret
patent: 5100908 (1992-03-01), Murata et al.
patent: 5152914 (1992-10-01), Forster et al.
patent: 5190917 (1993-03-01), Lezdey et al.
patent: 5562642 (1996-10-01), Smith et al.
patent: 5696110 (1997-12-01), Bourrain et al.
patent: 5837274 (1998-11-01), Shick et al.
patent: 5888478 (1999-03-01), Maurin
patent: 5939085 (1999-08-01), Jacobs et al.
patent: 5959137 (1999-09-01), Collin et al.
patent: 6071541 (2000-06-01), Murad
patent: 6143310 (2000-11-01), Sang et al.
patent: 6150400 (2000-11-01), Nyirjesy et al.
patent: 6150403 (2000-11-01), Biedermann et al.
patent: 6165479 (2000-12-01), Wheeler
patent: 6177092 (2001-01-01), Lentini et al.
patent: 6207694 (2001-03-01), Murad
patent: 6231844 (2001-05-01), Nambu
patent: 0 189 861 (1986-08-01), None
patent: 0 208 009 (1987-01-01), None
patent: 1 445 437 (1976-08-01), None
patent: 1 475 503 (1977-06-01), None
patent: 1 537 047 (1978-12-01), None
patent: 2 202 145 (1988-09-01), None
patent: 0157172 (1997-06-01), None
patent: 9157161 (1997-06-01), None
Dener et al. Abstract of WO 98/04537, published Feb. 5, 1998.
Handbook of Cosmetic Science and Technology, 1stEdition, 1993. Elsevier Science Publishers LTD, p. 67.
Haider SA. Treatment of atopic eczema in children-. A clinical trial of10% sodium cromoglycate ointment. BMJ (1977); 1570-1572.
Ariyanayagam et al (1985) Br J Dermatol 112(3), 343-348.
Merck Index twelth edition Budvari Ed (1996) excerpts relevant to documents 3 and 4.
Thirumoothy T, Greaves MW. Disodiumcromoglycate ointment in atopic eczema. BMJ (1978); 500-501.
Croner S, et al. Sodium cromoglycate ointment in atopic eczema during childhood. Opuscula Medica (1981) 26(2): 49-50.
Zachafiae H, Testrup-Pederson K, Thulin H, Thormann J, Herlin T, Cramers M, Jensen J, Kragballe K, Afzelius H, Overgaard Petersen H. Experimentaltreatment in atopic dermatitus: immunologial background & preliminary results. Acta Dermatovener (Stockholm) Suppl. (1980) 92:121-12.
Haider SA.. Treatment of atopic dermatitis in children.—Use of topical sodium cromoglycate. From The Mast Cell; Its role in Health and Desease. Eds. Pepys and Edwards (1979); Pitman Medical. 570-6.
Pearce CA, Greaves MW, Plummer VM. Yamamoto S. Effect of sodium cromoglycate on antigen evoked histamine release in human skin. Clin Exp Immunol (1974) 17:437-440.
Clegg LS, Church MK, Holgate ST. Histamine secretion from human skin slices induced by anti-lgE and artificial secretagogues and the effects of sodium cromoglycate and salbutamol. Clin Allergy(1985)15(4):321-328.
Okayama Y, Benyon RC, Rees PH, Lowman MA, Hillier K, Church MK. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Clin Exp Allergy (1992)22(3): 410-409.
Crossman DC, Dashwood NR Taylor GW, Wellings R, Fuller RW. Sodium cromoglycate: evidence of tachykinin antagonist activity in the human skin. J Appl Physiol (1993) 75(1): 167-172.
Walsh LJ. Ultraviolet B irradiation of skin induces mast cell degranulation and release of tumour necrosis factor. Immunology and Cell Biology (1995) 73: 226-233.
Page C. Sodium cromoglycate, a tachykinin antagonist. Lancet (1994) 343:70.
Edwards AM, Norffs AA. Cromoglycate and asthma. Lancet (1994) 343:426.
Ting S, Zweiman B, Lavker R. Cromolyn does not modulate human allergic skin reaction in vivo, J Allergy Clin Immunol (1983) 71(1 Pt 1): 12-17.
Van Bever HP, Stevens WJ. The effect of local application of disodium cromoglycate (DSCG) solution on skin prick tests. J Allergy Clin Immunol (1991)1:226A.
Gronneberg R, Zetterstrom O. Effect of local application of disodium cromoglycate on anti-1gE induced early and late skin response in humans. Clin Allergy (1985)15(2): 167-171.
Kimata H, Igarashi M. Inhibition of human allergic skin reactions in vivo by pretreatment with cromolyn (disodium cromoglycate). Allergy (1990)45:393-395.
Phillips TJ, Kanj LF, Washek D, Lew R. Topical cromolyn can modify human allergic skin reactions. Allergy (1996)51(3) 198-199.
Kjellman N-I M and Gustafsson IM. Topical sodium cromoglycate in atopic dermatitis. Allergy (1986)44(6): 423-428.
Pike MG and Atherton DJ. Failure of a new topical sodium cromo-glycate formulation to improve atopic dermatitis. Eur J Ped (1988)148(2): 170.
Neale MG, Brown K, Hodder Rw, Auty RM. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmac (1986)22:373-382.
Kimata H, Igarashi MIE. Topical cromolyn (disodium cromoglycate) solution in the treatment of young children with atopic dermatitis. Clin Exp Allergy (1990)20:281-283.
Kimata H, Hiratsuka S. Efect of topical sodium cromoglycate solu-tionon atopic dermatitis: combined treatment of sodium cromoglycate solution with the oral antiallergic medication, oxatomide. Eur J Pediatr (1994)153:66-71.
Hiratsuka S, Yoshida A, Ishioka C, Kimata H. Enhancement of in vitro spontaneous IgE production by topical steroids in patients with atopic dermatitis. J Allergy Clin Immunol (1996)98:107-113.
Loh RKS, Jabara HH, Geha RS. Disodium cromoglycate inhibits Sμ-Se deletional switch recombination and IgEsynthesis in Human B cells. J Exp Med (1994)180(2):663-671.
Wu CY, , Sarfati M, Heusser C, Poumeir S, Rubio-Trujillo M, Deles-pesse G. Glucocorticoids increase the synthesis of immunoglobulin E by interleukin-4 stimulated human lymphocytes. J Clin Invest (1991)87:870-877.
McHenry PM, Willimas HC, Bingham EA. Managementof atopic eczema. BMJ (1995)310:843-847.
Atopic dermatitis and cromolyn. Clin Exp Allergy (1990)20:243-244.
European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: The SCORAD index. Dermatiology (1993) 186:23-31.
Ishikura et al (1987) Drug Design & Delivery 1, 285-295.
Van Bever & Stevens (1989) Eur J Pediatr 149, 74.
Cox JSG et al. Disodium Cromoglycate (Intal. Advances in Drug Research) (1970): 5,115-196.
Moore C et al. Topical sodium cromoglycate in the treatment of moderate to sever atopic dermatitis. Ann Allergy Asthma Immunol (1998)81, 452-458.
Church MK et al. Cromolyn sodium and nedocromil sodium: mast cell stabilizers, neuromodulators or anti-immflamatory drugs? In Kaliner MA et al (eds). Asthma: its pathology and treatment. New York: Marcel Dekker, (1991)561-593.
Jackson DM et al. The effects of sodium cromoglycate on histamine aerosol-induced reflex bronchoconstriction in the anaesthetized dog. Br J Pharmac (1977)61,257-262.
Dixon M et al. The action of sodium cromoglycate on “C” fibre endingsin the dog lung. Br J Pharmacol(1980)70,11-13.
Richard IM et al. Alternative modes of action of sodium cromoglycate. Agents Actions (1986)18(3/4), 294-300.
Collier JG et al. Evidence for an effect of sodium cromoglycate on sensory nerves in man. Br J Clin Pharmacol (1983)16,639-643.
Haugen Law Firm PLLP
Hewlett Healthcare Ltd
Padmanabhan Sreeni
Yu Gina C.
LandOfFree
Pharmaceutical compositions comprising an amphoteric... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions comprising an amphoteric..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions comprising an amphoteric... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3532310